A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors

Recruiting

• Conditions: Head and Neck Cancer; Cervical Cancer; Non Small Cell Lung Cancer; Melanoma; Ovarian Cancer; HPV16 Related Cancers

• Registration Number: NCT05812027
• Lead Sponsor: TScan Therapeutics, Inc.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-3-31
• Last Update Posted: 2 September 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 650

Inclusion Criteria

Inclusion Criteria:<br><br> - Willing and able to provide written informed consent.<br><br> - Male or female aged =18 years at the time of signing the informed consent.<br><br> - Have one of the following histologically or cytologically confirmed locally advanced<br> (unresectable) or metastatic solid tumor:<br><br> - Head and neck cancer<br><br> - Cervical cancer<br><br> - Non-small cell lung cancer<br><br> - Melanoma<br><br> - Ovarian cancer<br><br> - HPV positive anogenital cancers<br><br> - Other cancers with a reasonable likelihood of expressing 1 or more antigens included<br> in a TScan clinical trial, following approval by the TScan Medical Monitor or their<br> delegate.<br><br> - Willing to provide a buccal swab for HLA testing<br><br> - Willing to provide a saliva sample to use as a normal control for the LOH assay<br><br> - Have access to an FFPE tumor block that is <8 months old or is willing to provide a<br> fresh core-needle biopsy.<br><br>Exclusion Criteria:<br><br>• Participants undergoing anticancer therapy with curative intent such as tumor surgical<br>resection with or without neoadjuvant/adjuvant therapy, or definitive chemoradiation,<br>unless they have locoregionally advanced disease and are expected to have a high risk of<br>relapse after their curative intent therapy as determined by the treating investigator.

Exclusion Criteria

Not provided

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Frequency of subjects with TAA expression, HLA typing and HLA loss.